Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of prior cilta-cel-treated participants
jRCT2033220220Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with new malignancies and recurrence of pre-existing malignancy, Number of participants with new incidence or exacerbation of a pre-existing neurologic disorder and 7 more. Started Jul 2022; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2033220220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033220220.